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Abstract
Objectives: This study evaluates current trends in incidence, clinical outcomes and factors predictive of
survival in children with hepatoblastoma (HB).
Methods: The Surveillance, Epidemiology and End Results (SEER) database was queried for the period
1973–2009 for all patients aged <20 years with HB.
Results: A total of 606 patients were identified. The age-adjusted incidence was 0.13 patients per
100 000 in 2009. An annual percentage change of 2.18% (95% confidence interval (CI) 1.10–3.27; P <
0.05) was seen over the study period. Overall survival rates at 5, 10 and 20 years were 63%, 61% and
59%, respectively. Ten-year survival rates significantly improved in patients with resectable disease who
underwent operative treatment in comparison with those with non-resectable HB (86% versus 39%; P <
0.0001). Multivariate analysis showed surgical treatment (hazard ratio (HR) = 0.23, 95% CI 0.17–0.31;
P < 0.0001), Hispanic ethnicity (HR = 0.61, 95% CI 0.43–0.89; P = 0.01), local disease at presentation
(HR = 0.43, 95% CI 0.29–0.63; P < 0.0001) and age < 5 years (HR = 0.63, 95% CI 0.41–0.95; P < 0.03) to
be independent prognostic factors of survival.
Conclusions: The incidence of paediatric HB has increased over time. Hepatoblastoma is almost
exclusively seen in children aged < 5 years. When HB presents after the age of 5 years, the prognosis is
most unfavourable. Tumour extirpation markedly improves survival in paediatric patients with local
disease.
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Introduction
Primary hepatic malignancies are rare during childhood, repre-
senting 1% of all paediatric neoplasms.1–4 A total of 80% of all
hepatic malignancies can be identified as hepatoblastoma
(HB),3,5,6 which is arguably the most common primary liver cancer
in infants and children and occurs at an annual incidence of
0.05–0.15 patients per 100 000 population in subjects aged < 15
years.1,7 In children aged < 5 years, 91% of liver malignancies are
diagnosed as HB3,5,6 and only 5% of HBs are seen in patients aged
>4 years.5,8
Hepatoblastoma most frequently affects children between the
ages of 6 months and 3 years, at a median age of 18 months.1,8 It is
slightly more predominant in White males,1 is seen more fre-
quently in association with premature birth and very low birth-
weight2,9 and in patients with genetic alterations such as familial
adenomatous polyposis syndrome.1
Complete tumour resection remains the cornerstone of treat-
ment,10 but since the addition of chemotherapy in the 1980s,
the overall survival rate has increased markedly from 30%.11
Various groups have suggested different approaches to treatment;
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(SIOPEL) suggests chemotherapy should be administered before
the resection of the tumour, whereas the Children’s Oncology
Group (COG), along with Japanese and German groups, suggests
the tumour should first be resected for staging and chemotherapy
administered subsequently.10 Both approaches have achieved
similar clinical outcomes with 5-year overall survival rates of
>70%.1,7,10–12
The purpose of the present study was to analyse current trends
in tumour incidence and clinical outcomes and the factors pre-
dictive of survival in a large sample of paediatric patients with HB.
Materials and methods
The Surveillance, Epidemiology and End Results (SEER) data-
base released on July 2012 was analysed to identify all incident
patients with primary HB diagnosed between 1973 and 2009.
Tumour location and histology were based upon topography and
morphology codes according to the International Classification
of Diseases for Oncology, third edition (ICD-O-3). The SEER
database was first queried for all patients aged < 20 years with
primary malignant hepatic tumours (topography code: C22.0). A
total of 946 patients with primary malignant liver tumours were
identified in the SEER database. Of these, 606 patients were iden-
tified as diagnosed with HB (ICD-O-3 code: 8970) and included
in this analysis. There were no duplicate patients. Only percent-
ages based on available data for each individual variable are
given. Unknown values were excluded from all calculations.
SEER*Stat software (Version 7.1.0; National Cancer Institute,
Bethesda, MD, USA) was used to analyse incidence rates and
trends from 1973 to 2009. All incidence data were age-adjusted
and normalized to the 2000 US Standard Population. The annual
percentage change (APC) was calculated using the weighted least
squares method.
The tumour staging criteria used in this analysis were adopted
from the SEER summary staging guidelines and differ from the
tumour–node–metastasis (TNM) staging system. In this study,
local staging represents disease that does not extend beyond the
primary organ, whereas regional disease includes tumour exten-
sion to adjacent organs, regional lymph nodes or both. Docu-
mentation of distant metastases during the perioperative period
led to the classification of affected patients as having distant
disease.
Statistical analysis was performed using IBM spss Statistics 20.0
(IBM Corp., Armonk, NY, USA). Correlations between categorical
variables were made using the chi-squared test. Data with a
normal distribution were compared using Student’s t-test and
non-parametric data were compared using the Mann–Whitney
U-test. Five, 10- and 20-year overall survival rates were calculated
using life tables. The Kaplan–Meier method was used to calculate
survival curves. Survival was calculated from the time of initial
diagnosis to the date of last contact (or the date of death if the
patient was deceased). The effects of demographic, clinical and
treatment variables on survival were tested by utilizing the log-
rank test for categorical values. Values are expressed as appropriate
as the mean standard deviation, median (interquartile range) or
number (percentage). Cox’s logistic regression was used to iden-
tify predictors of survival using all variables found to be signifi-
cant (P < 0.05) or near significant (P < 0.10) in univariate analysis
or if clinically significant.
Results
Patient demographics and tumour characteristics
For the study period, a total of 606 patients were identified. The
overall age-adjusted incidence of paediatric malignant liver
tumours was 0.174 patients per 100 000 children with a statisti-
cally significant increase in incidence per year, leading to an APC
of 1.79% [95% confidence interval (CI) 0.74–2.84; P < 0.05]. This
increase in incidence may be largely attributed to an increase in
incidence per year of HBs, resulting in an APC of 2.18% (95% CI
1.10–3.27; P < 0.05) (Fig. 1). Patient demographics and tumour
characteristics are summarized in Table 1.
Survival
Overall survival rates at 5, 10 and 20 years for the entire cohort
were 63%, 61% and 59%, respectively. These results were consist-
ent for up to 20 years after diagnosis. Overall survival rates are
summarized in Table 2. Notably, age at diagnosis emerged as an
important clinical indicator of disease prognosis. Adolescent
patients had the lowest 5-year survival rate and none of these
patients remained alive at 10 years after diagnosis. However, the
occurrence of HB after the age of 10 years is exceedingly rare and
only 18 such patients were reported in the SEER database for the
study period. With reference to interventions, tumour resection
improved survival in patients with resectable disease (Fig. 2).
Results of the univariate and multivariate analyses using a Cox
regression model are summarized in Table 3. Age at diagnosis,
patient ethnicity, tumour stage and surgical resection were all
identified as independent predictors of survival.
Discussion
Although HB is the most frequent primary malignant hepatic
tumour in children, it is quite rare and occurs in fewer than one
subject per 100 000 births.13 Nonetheless, the prompt diagnosis
and management of HB with chemotherapy and/or surgical resec-
tion remain paramount in treating these patients, who most often
present with a mass in the upper right quadrant of the abdomen
or with an evident epigastric abdominal mass. This study was
conducted to analyse current trends in tumour incidence, and
clinical outcomes and factors predictive of survival in a large
sample of paediatric patients with HB.
Similarly to findings in recent reports on HB,1,3,5,6,13,14 analysis of
data in the present cohort of patients showed that HB appeared
most frequently in males (59.4%), Whites (80.7%) and children
aged < 5 years (91.6%). Furthermore, an increasing number of
patients are now diagnosed antenatally by routine sonography.15–19
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Specifically, within this analysis, the second most commonly
affected age group comprised infants aged < 1 year (34.5%), fol-
lowed by children aged 5–9 years (5.4%), children aged 10–14
years (2.1%) and, lastly, adolescents aged 15–19 years (0.8%). As
expected, the age group most commonly affected by HB in this
study included children aged 1–4 years (57.1%).
Several studies have reported the incidence of malignant liver
tumours to be increasing in the USA.8,20,21 For the period 1972–
1992, the SEER database showed an annual increase of 5% in the
rate of primary paediatric hepatic cancer.20 Other data showed
that liver cancer represented 2% of all malignancies in infants in
the early 1980s, with the incidence doubling to 4% over the next
10 years.21 Similarly, the present study determined a statistically
significant increase in the overall age-adjusted incidence of pae-
diatric malignant liver tumours for the period 1973–2009, leading
to an APC of 1.79%. This increase may potentially be attributed to
an increase in the annual incidence of HB, leading to an APC of
2.18% over the 37-year period. Lastly, it has been suggested that
improvements in technology, patient care and outcomes for pre-
mature infants may account for the increased incidence of paedi-
atric HB. Other factors, such as better diagnosis and coding, may
also have contributed to the observed increase in incidence.
Complete surgical resection remains the cornerstone of treat-
ment in paediatric patients with HB; without this, patient prog-
nosis remains grave. The COG recommends a post-surgical
staging system based on operative findings. According to the
COG, stage I disease refers to a tumour that is completely resected.
Microscopic residual tumour after resection is designated as stage
II. Stage III is used for tumours with no distant metastasis but
positive lymph nodes or unresectable or gross residual tumour.
Lastly, stage IV is applied to cases of distant metastasis irrespective
of tumour extent.10 If left untreated, patients with HB may die
within < 2 years.22–25 Over three-quarters of the patient population
within this study underwent surgical resection for the presence of
an HB. Furthermore, 68.8% of patients presented with resectable
disease situated either locally or regionally, and the remainder had
either distant metastasis (26.9%) or unstaged disease (4.3%).
Whereas HB was formerly a disease with a dreadful prognosis,
children with HB now have a 5-year survival rate of >70% as a
result of the advent of treatment regimens comprising both sys-
temic chemotherapy and surgery.11 Because of the different thera-
peutic strategies used, which involve adjuvant versus neoadjuvant
chemotherapy, there is no universal system for selecting patients
for treatment. In general, patients with tumours that are com-
pletely resected at the time of surgery and favourable tumour
histology can be cured with surgery alone.26 Conversely, patients
with unfavourable tumour biology, unresectable tumours prior to
surgery, tumours that are incompletely resected at the time of
surgery or locoregional disease benefit from chemotherapy.27,28
Nevertheless, additional issues regarding risk group stratification,
and the treatment of recurrent or refractory disease remain to be
determined and treatment strategies remain under debate.10 In
this study, survival rates at 5, 10 and 20 years post-HB resection
were consistently 74%, and were significantly greater than those in
patients who did not undergo surgical intervention. Furthermore,
girls achieved better survival rates to 10 years than boys. However,
there is no scientific evidence of gender-specific factors that might
account for the observed differences in survival. Chemotherapy
information is not reported in the SEER database.
In the 1980s, 5-year overall survival in children with HB was
about 30%.11 Within this surgical series, overall survival rates
post-treatment were 63% at 5 years, 61% at 10 years and 59% at 20
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Figure 1 Incidence of hepatoblastoma in children over a 37-year period. The incidence of hepatoblastoma has increased over time
(annual percentage change = 2.18%; P < 0.05), in line with increases in the incidence of all primary tumours of the liver in the paediatric
population
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years. The highest survival rates were found for males in compari-
son with females (P = 0.001), the presence of local disease as
opposed to regional or distant metastasis (P = 0.001) and surgical
extirpation versus no operative management (P = 0.001). Specifi-
cally, patients with local disease achieved a survival rate of 80% at
5, 10 and 20 years post-diagnosis, whereas patients with distant
disease achieved survival rates close to 40% at all three time-
points. Furthermore, survival rates were highest for children diag-
nosed at < 5 years of age and peaked to 64% in the neonatal group
at 5, 10 and 20 years post-diagnosis. Therefore, age is an important
clinical indicator of prognosis; adolescent patients had the lowest
5-year survival rate at 20% and no adolescent patients remained
alive at 10 years after diagnosis. However, the incidence of HB in
subjects aged >10 years is low and only 18 such patients were
identified in the SEER database for the study period. In addition to
age and surgical resection, multivariate analysis determined that
ethnicity and tumour stage are also independent predictors of
survival in patients with HB.
There are several limitations inherent within the SEER data-
base. This was a retrospective review of data collected by the
National Cancer Institute, the coverage of which is limited to
about 26% of the total US population. The study sample size was
Table 1 Demographic characteristics of 606 paediatric patients with
hepatoblastomas registered in the Surveillance, Epidemiology and
End Results (SEER) database
Age, years, median (range) 1 (0–19)
Gender, n (%)
Male 360 (59.4%)
Female 246 (40.6%)
Age, n (%)
<1 year 209 (34.5%)
1–4 years 346 (57.1%)
5–9 years 33 (5.4%)
10–14 years 13 (2.1%)
15–19 years 5 (0.8%)
Race, n (%)
White 489 (80.7%)
Black 46 (7.6%)
Asian 66 (10.9%)
Other 5 (0.8%)
Ethnicity, n (%)
Non-Hispanic 438 (72.3%)
Hispanic 168 (27.7%)
Tumour stage, n (%)
Local 253 (41.7%)
Regional 164 (27.1%)
Distant 163 (26.9%)
Unstaged 26 (4.3%)
Surgery, n (%)
No 142 (23.4%)
Yes 464 (76.6%)
Radiation, n (%)
No 587 (96.9%)
Yes 19 (3.1%)
Table 2 Overall survival at 5, 10 and 20 years in 606 paediatric
patients with hepatoblastoma
Survival at
5 years
Survival at
10 years
Survival at
20 years
P-value
Gender 0.001
Male 62% 60% 60%
Female 63% 63% 58%
Age group 0.001
<1 year 64% 64% 64%
1–4 years 64% 63% 59%
5–9 years 44% 44% 44%
10–14 years 34% 34% 34%
15–19 years 20% 0% NR
Tumour stage 0.001
Local 80% 80% 80%
Regional 59% 57% 52%
Distant 42% 39% 39%
Surgery 0.001
No 28% 25% 25%
Yes 74% 74% 74%
NR, not reached.
Figure 2 Kaplan–Meier survival curves for paediatric patients with
hepatoblastoma and resectable disease at presentation. Survival in
patients with local disease is significantly better in those undergoing
tumour resection compared with that in patients who do not undergo
surgery (P < 0.0001)
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relatively small and thus there is a potential decrease in power,
leading to the possibility of a type II error. The influence of pre-
maturity and the impact of associated anomalies on outcomes
cannot be evaluated. Furthermore, assessing patient symptoma-
tology on initial presentation, determining the resolution of such
symptoms after treatment and evaluating the use of chemo-
therapy as a treatment regimen remain beyond the scope of this
database. Lastly, given that minority racial and ethnic groups are
of special interest to the SEER programme, they may be somewhat
over-represented within the database. Nonetheless, the SEER
database is considered the standard among cancer registries and
its value has been validated in numerous publications pertaining
to paediatric cancer outcomes.29–35
In conclusion, HB is an uncommon liver malignancy seen
mostly in children aged < 5years. The dramatic increase in survival
can be attributed, in part, to surgical resection of the disease.
However, given the increase in disease incidence over time, the
evaluation of reliable prognostic factors remains paramount in
supporting the prompt diagnosis and optimum management of
paediatric patients with HB.
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